Dashboard
Manage Tickers

COCP Cocrystal Pharma, Inc.

Nasdaq cocrystalpharma.com


$ 1.05 $ 0.02 (1.9 %)    

Thursday, 16-Oct-2025 16:45:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 597.93 $ -2.23 (-0.37 %)
DIA $ 458.28 $ -3.15 (-0.68 %)
SPY $ 658.51 $ -4.53 (-0.68 %)
TLT $ 91.38 $ 0.68 (0.75 %)
GLD $ 400.19 $ 9.06 (2.34 %)
$ 1.07
$ 1.06
$ 1.04 x 2,332
$ 1.06 x 7
$ 1.04 - $ 1.09
$ 1.02 - $ 3.26
157,391
na
10.98M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-17-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-21-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/15/2025 12:10:36

cocrystal-pharma-reveals-up-to-13m-registered-direct-offering
Cocrystal Pharma Reveals Up To $13M Regist...
09/12/2025 13:53:26

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (NASDAQ:COCP) (the "Company" or "Cocryst...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/12/2025 12:09:50

cocrystal-pharma-highlights-cdi-988-as-first-oral-antiviral-candidate-for-norovirus-at-9th-international-calicivirus-conference
Cocrystal Pharma Highlights CDI-988 As Fir...
09/12/2025 12:02:56

Cocrystal Pharma, Inc. (NASDAQ:COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and c...

cocrystal-pharma-receives-study-may-proceed-letter-from-fda-to-conduct-phase-1b-challenge-study-evaluating-cdi-988-for-prevention-and-treatment-of-norovirus-infections-phase-1b-challenge-study-is-planned-to-begin-before-year-end-2025
Cocrystal Pharma Receives Study May Procee...
09/08/2025 12:01:58

There are currently no approved vaccines or treatments for norovirus infectionCocrystal's CDI-988 is the first antiviral fo...

cocrystal-pharma-q2-eps-020-beats-030-estimate
Cocrystal Pharma Q2 EPS $(0.20) Beats $(0....
08/14/2025 12:13:48

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0....

cocrystal-pharma-presents-phase-1-results-for-pan-viral-inhibitor-cdi-988-at-dod-medical-conference-including-that-all-cdi-988-doses-ranging-from-100-mg-to-1200-mg-in-phase-1-study-were-well-tolerated-company-expects-to-initiate-phase-1b-study-with-cdi-988-in-norovirus-infected-healthy-subjects-later-this-year
Cocrystal Pharma Presents Phase 1 Results ...
08/05/2025 12:05:15

All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

cocrystal-pharma-presents-phase-1-study-data-of-first-in-class-norovirus-protease-inhibitor-cdi-988-at-9th-international-calicivirus-conference
Cocrystal Pharma Presents Phase 1 Study Da...
07/10/2025 12:13:47

hc-wainwright--co-maintains-buy-on-cocrystal-pharma-lowers-price-target-to-6
HC Wainwright & Co. Maintains Buy on Cocry...
06/20/2025 11:16:55

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price ...

cocrystal-pharmas-recent-virology-study-shows-broad-spectrum-influenza-pb2-inhibitor-cc-42344-exhibits-strong-antiviral-activity-against-highly-pathogenic-h5n1-avian-influenza-a-strain
Cocrystal Pharma's Recent Virology Study S...
05/29/2025 12:03:30

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strainThe Company's vi...

cocrystal-pharma-q1-eps-023-beats-051-estimate
Cocrystal Pharma Q1 EPS $(0.23) Beats $(0....
05/15/2025 12:18:35

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0....

cocrystal-pharma-announces-norovirus-oral-antiviral-candidate-demonstrates-potent-activity-against-the-emerging-gii17-variants
Cocrystal Pharma Announces Norovirus Oral ...
04/24/2025 12:01:54

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in ...

hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Cocr...
01/22/2025 12:54:56

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $7 pri...

cocrystal-pharma-reports-phase-1-results-with-oral-broad-acting-antiviral-drug-cdi-988-for-prophylaxis-and-treatment-of-norovirus-coronaviruses-and-other-viral-infections-data-show-favorable-safety-and-tolerability-with-dosing-up-to-800-mg-for-10-days-plans-to-initiate-human-challenge-study-in-2025-in-norovirus-infected-subjects
Cocrystal Pharma Reports Phase 1 Results W...
01/08/2025 13:12:06

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
12/31/2024 21:05:53

dow-dips-over-100-points-cocrystal-pharma-shares-slide
Dow Dips Over 100 Points; Cocrystal Pharma...
12/31/2024 19:21:35

crude-oil-rises-1-sangamo-therapeutics-shares-plummet
Crude Oil Rises 1%; Sangamo Therapeutics S...
12/31/2024 17:01:49

us-stocks-open-higher-house-prices-increase-in-october
US Stocks Open Higher; House Prices Increa...
12/31/2024 15:02:31

cocrystal-pharma-plans-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344-due-to-low-influenza-infection-among-challenged-participants
Cocrystal Pharma Plans To Extend Phase 2a ...
12/31/2024 13:03:11

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION